multiple myeloma

Multiple myeloma is a plasma cell malignancy that remains incurable but has seen dramatic improvements in survival from combination therapy incorporating proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies, and CAR-T cell therapy. Measurable residual disease negativity is increasingly used as a surrogate endpoint for regulatory submissions. Quadruplet induction regimens and maintenance strategies are defining the standard of care in transplant-eligible patients.